In a metaanalysis of eight placebo-controlled, double-blind trials, 552 obese patients with type 2 diabetes were randomized to sibutramine treatment, and 541 were randomized to placebo. Body weight decreased by a mean of 5.5 kg in sibutramine users and by 0.9 kg in placebo users. Waist circumference decreased a mean of 5.3 cm in treated patients and by 1.1 cm with placebo (Diabetes Care 2005;28:942-9).
Mean changes in basal blood glucose were small, but the difference between the two groups was statistically significant, the investigators said. Treatment benefits also were seen in the levels of glycated hemoglobin (Hb[A.sub.1c]), serum triglycerides, and HDL cholesterol.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||CLINICAL CAPSULES|
|Publication:||Internal Medicine News|
|Article Type:||Brief Article|
|Date:||Jul 1, 2005|
|Previous Article:||Predicting metabolic syndrome.|
|Next Article:||BMI tied to meniscal tears.|